Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | |||
---|---|---|---|---|---|---|
Aktuell sind keine Nachrichten verfügbar, die den gewählten Kriterien entsprechen. |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
SANOCHEMIA PHARMAZEUTIKA | - | - | Nachlese: Magnus Brunner vs. FMA" EOSS holt nach Sanochemia auch BDI BioEnergy; Bettina Pfluger (Christian Drastil) | Um 12:12 liegt der ATX mit +0.03 Prozent im Plus bei 3452 Punkten (Ultimo 2023: 3435, 0.49% ytd). Topperformer der PIR-Group sind Addiko Bank mit +1.82% auf 15.425 Euro, dahinter DO&CO mit +1.79% auf... ► Artikel lesen | |
IONIS PHARMACEUTICALS | 36,080 | -0,58 % | Ionis Pharmaceuticals, Inc.: Ionis reports first quarter 2024 financial results | WAINUATM launch on track; EU and Canada approval decisions expected this year
Olezarsen NDA submitted to FDA for FCS; preparing EU regulatory submission
Positive Phase 3 donidalorsen data for HAE;... ► Artikel lesen | |
CSPC PHARMA | 0,810 | -0,76 % | CSPC Pharmaceutical Group-Aktie kann Vortagsniveau nicht halten (0,686 €) | Im Minus liegt zur Stunde die Aktie der CSPC Pharmaceutical Group . Das Wertpapier kostete zuletzt 0,69 Euro. An der Börse liegt die CSPC Pharmaceutical Group-Aktie aktuell im Minus. Die Aktie verbilligte... ► Artikel lesen | |
SELLAS LIFE SCIENCES | 1,266 | +0,64 % | SELLAS Life Sciences Group, Inc.: SELLAS Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level | - The Company Filed IP Protection Related to the ASXL1 Mutation, a Highly Prevalent Gene Mutation in Myeloid Malignancies and Solid Tumors With Significant Market Potential - - 100% Overall Response... ► Artikel lesen | |
ACADIA PHARMACEUTICALS | 14,195 | +0,28 % | Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview | SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced its financial results for the first quarter ended March 31, 2024.
"In the first quarter of 2024, Acadia... ► Artikel lesen | |
MADRIGAL PHARMACEUTICALS | 189,75 | -0,52 % | Madrigal Pharmaceuticals, Inc. (MDGL) Q1 2024 Earnings Call Transcript | ||
CATALYST PHARMACEUTICALS | 14,605 | -1,28 % | Catalyst Pharmaceuticals, Inc.: Catalyst Pharmaceuticals Reports Solid First Quarter 2024 Financial Results and Provides Business Update | Achieved Total Q1 2024 Revenues of $98.5 Million, a 15.4% YoY Increase, Underscored by Exceptional Execution and Continued Demand for Commercial Products FIRDAPSE® Q1 2024 Net Product Revenues of... ► Artikel lesen | |
ENZON PHARMACEUTICALS | 0,065 | 0,00 % | ENZON PHARMACEUTICALS, INC. - 10-Q, Quarterly Report | ||
OCUPHIRE PHARMA | 1,600 | +0,50 % | Ocuphire Pharma Announces Financial Results for First Quarter 2024 and Provides Corporate Update | FARMINGTON HILLS, Mich., May 10, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing small molecule therapies... ► Artikel lesen | |
DMK PHARMACEUTICALS | 0,049 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 13.02.2024 - 2 | The following instruments on Boerse Frankfurt do have their last trading day on 13.02.2024Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 13.02.2024ISIN NameLU0102219945 G.SACHS... ► Artikel lesen | |
VIRACTA THERAPEUTICS | 0,740 | -1,33 % | Viracta Therapeutics GAAP EPS of -$0.23 | ||
ELITE PHARMACEUTICALS | - | - | Elite Pharmaceuticals, Inc. Reports Financial Results for Third Quarter of Fiscal Year 2024 ended December 31, 2023 and Provides Conference Call Information | Conference Call Scheduled for Thursday, February 15 at 11:30 AM ESTNORTHVALE, NJ / ACCESSWIRE / February 14, 2024 / Elite Pharmaceuticals, Inc. ("Elite" or the "Company")(OTCBB:ELTP), a specialty pharmaceutical... ► Artikel lesen | |
SAVARA | 4,840 | +12,04 % | Savara Reports First Quarter 2024 Financial Results and Provides Business Update | LANGHORNE, Pa.--(BUSINESS WIRE)--Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first... ► Artikel lesen | |
GALECTIN THERAPEUTICS | 2,780 | -6,71 % | Galectin Therapeutics Inc expected to post a loss of 16 cents a share - Earnings Preview | ||
BIODEXA PHARMACEUTICALS | 0,945 | +9,88 % | Biodexa Pharmaceuticals Plc: Biodexa Looks To Prevent Or Delay The Worst Outcomes For Adolescents And Young Adults With Devastating Precancerous Condition | Registrational phase 3 clinical trials of Biodexa's (NASDAQ:BDRX) candidate eRapa are expected to start first quarter next year.The candidate was developed with private funds and acquired by Biodexa... ► Artikel lesen |